Comparative Effect of the I3.1 Probiotic Formula in Two Animal Models of Colitis.
Use of probiotic therapy is an active area of investigation to treat intestinal disorders. The clinical benefits of the I3.1 probiotic formula (Lactobacillus plantarum (CECT7484, CECT7485) and P. acidilactici (CECT7483)) were demonstrated in irritable bowel syndrome (IBS) patients in a randomized, double-blind, placebo-controlled clinical trial. The aim of this study was to evaluate the therapeutic effects of I3.1 in two experimental models of colitis, a dextran sulfate sodium (DSS)-induced colitis model and an interleukin (IL)-10-deficient mice model. Colitis was induced in 32 8-week-old Balb/c mice by administering 3% (w/v) DSS in drinking water for 5 days. Probiotics were administered orally (I3.1 or VSL#3, 1 × 109CFU daily) for 10 days before the administration of DSS. Also, probiotics (I3.1 or VSL#3, 1 × 109CFU daily) were administered orally to 36 6-week-old C57B6J IL-10(-/-) mice for 10 weeks. Body weight was recorded daily. Colon samples were harvested for histological examination and cytokine measurements. Body weight after DSS administration did not change in the I3.1 group, whereas the VSL#3 group had weight loss. Also, I3.1 normalized IL-6 to levels similar to that of healthy controls and significantly increased the reparative histologic score. In the IL-10-deficient model, both VSL#3 and I3.1 reduced the severity of colitis compared to untreated controls, and I3.1 significantly reduced the levels of IFN-γ compared to the other two groups. In conclusion, I3.1 displays a protective effect on two murine models of experimental colitis. Results suggest that the mechanism of action could be different from VSL#3.
Health Sciences Research Institute, University Hospital "Germans Trias i Pujol", Ctra. de Can Ruti. Cami de les escoles s/n, 08916, Badalona, Spain.|CIBER-EHD, 28029, Madrid, Spain.
Violeta
V
Lorén
Health Sciences Research Institute, University Hospital "Germans Trias i Pujol", Ctra. de Can Ruti. Cami de les escoles s/n, 08916, Badalona, Spain. josep.manye@ciberehd.org.|CIBER-EHD, 28029, Madrid, Spain. josep.manye@ciberehd.org.
Josep
J
Manyé
AB-Biotics S.A, Autonomous University of Barcelona, Eureka Building, 08193, Bellaterra, Spain.
Mari C
MC
Fuentes
CIBER-EHD, 28029, Madrid, Spain.|IBD Unit, Gastroenterology Department, University Hospital "Germans Trias i Pujol", 08916, Badalona, Spain.
Eduard
E
Cabré
Pathology Department, University Hospital "Germans Trias i Pujol", 08916, Badalona, Spain.
Isabel
I
Ojanguren
AB-Biotics S.A, Autonomous University of Barcelona, Eureka Building, 08193, Bellaterra, Spain.
Jordi
J
Espadaler
D000818:Animals; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000382:microbiology; D016264:Dextran Sulfate / Q000009:adverse effects; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology; D015850:Interleukin-6 / Q000276:immunology; D048191:Lactiplantibacillus plantarum / Q000502:physiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D019936:Probiotics / Q000008:administration & dosage*
D015850:Interleukin-6; D007371:Interferon-gamma; D016264:Dextran Sulfate
Colitis; Interferon-gamma; Interleukin-6; Lactobacillus plantarum; Pediococcus acidilactici; Probiotics; TNF-alpha